NCT05294731

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Recruiting now Phase 1, PHASE2 Last updated 17 April 2026

What this trial tests

Phase 1, PHASE2 trial testing BGB-16673 in B-cell Malignancy in 146 participants. Currently enrolling.

Timeline

6 May 2022

Primary endpoint
31 January 2029

31 January 2029

Quick facts

Lead sponsor	BeiGene
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	146
Start date	6 May 2022
Primary completion	31 January 2029
Estimated completion	31 January 2029
Sites	29 locations across China

Drugs / interventions tested

• BGB-16673 — full drug profile →

Conditions studied

• B-cell Malignancy — all drugs for B-cell Malignancy →
• Non-Hodgkin Lymphoma — all drugs for Non-Hodgkin Lymphoma →
• Mantle Cell Lymphoma — all drugs for Mantle Cell Lymphoma →
• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — all drugs for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma →

Sponsor

BeiGene — full company profile →

Who can join

18 and older, any sex, with B-cell Malignancy or Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeted protein degradation: advances in drug discovery and clinical practice.
   Zhong G, Chang X, Xie W, Zhou X. · · 2024 · cited 112× · PMID 39500878 · DOI 10.1038/s41392-024-02004-x
2. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
   Li R, Liu M, Yang Z, Li J, et al · · 2022 · cited 45× · PMID 36557960 · DOI 10.3390/molecules27248828
3. Protein degradation: expanding the toolbox to restrain cancer drug resistance.
   Ming H, Li B, Jiang J, Qin S, et al · · 2023 · cited 42× · PMID 36694209 · DOI 10.1186/s13045-023-01398-5
4. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
   Mouhssine S, Maher N, Matti BF, Alwan AF, et al · · 2024 · cited 20× · PMID 38542207 · DOI 10.3390/ijms25063234
5. RIPTACs: A groundbreaking approach to drug discovery.
   Ma Z, Bolinger AA, Zhou J. · · 2023 · cited 20× · PMID 37734702 · DOI 10.1016/j.drudis.2023.103774
6. Targeted Protein Degradation: Clinical Advances in the Field of Oncology.
   Salama AKAA, Trkulja MV, Casanova E, Uras IZ. · · 2022 · cited 19× · PMID 36499765 · DOI 10.3390/ijms232315440
7. Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.
   Bouvier C, Lawrence R, Cavallo F, Xolalpa W, et al · · 2024 · cited 14× · PMID 38607017 · DOI 10.3390/cells13070578
8. New Means and Challenges in the Targeting of BTK.
   Nawaratne V, Sondhi AK, Abdel-Wahab O, Taylor J. · · 2024 · cited 12× · PMID 38578606 · DOI 10.1158/1078-0432.ccr-23-0409